Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Basic toxicokinetics

Currently viewing:

Administrative data

Endpoint:
basic toxicokinetics in vivo
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Study well documented, meets generally accepted scientific principles, acceptable for assessment.

Data source

Referenceopen allclose all

Reference Type:
publication
Title:
Dissertation: Quadrol, N, N, N', N'-Tetrakis(2-Hydroxypropyl)ethylenediamine: pharmacokinetics and assessment of acute toxicity.
Author:
Dunphy MJ
Year:
1991
Bibliographic source:
Graduate Faculty of the University of Akron
Reference Type:
publication
Title:
Dissertation: Quadrol, N, N, N', N'-Tetrakis(2-Hydroxypropyl)ethylenediamine: pharmacokinetics and assessment of acute toxicity.
Author:
Dunphy MJ
Year:
1991
Bibliographic source:
Dissertation Abstracts International B52/02, 762, Order No. 9119922

Materials and methods

Objective of study:
absorption
distribution
excretion
metabolism
toxicokinetics
Test guideline
Qualifier:
no guideline followed
Principles of method if other than guideline:
Kinetics of absorption, distribution, metabolism and excretion of ethylenediamine, +4PO in orally and intravenously treated rats were determined.
GLP compliance:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
1,1',1'',1'''-ethylenedinitrilotetrapropan-2-ol
EC Number:
203-041-4
EC Name:
1,1',1'',1'''-ethylenedinitrilotetrapropan-2-ol
Cas Number:
102-60-3
Molecular formula:
C14H32N2O4
IUPAC Name:
1-({2-[bis(2-hydroxypropyl)amino]ethyl}(2-hydroxypropyl)amino)propan-2-ol
Details on test material:
- Name of test material (as cited in study report): Quadrol
- Physical state: viscous liquid
- Analytical purity: >90 %
- Impurities (identity and concentrations): no data

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Zivic Miller Laboratories
- Weight at study initiation: 250 - 300 g
- Housing: no data
- Individual metabolism cages: yes, but only for urine analysis
- Diet: standard rodent chow, ad libitum
- Water: ad libitum
- Acclimation period: one week


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22-25
- Humidity (%): 50-60
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:
other: oral gavage and intravenously
Vehicle:
water
Duration and frequency of treatment / exposure:
One single administration either by oral gavage or i.v. via surgically implanted jugular vein cannula or caudal vein
Doses / concentrations
Remarks:
Doses / Concentrations:
50, 100, 200 mg/kg bw i.v. via implanted jugular cannula or orally by gavage
100 mg/kg i.v. via caudal vein
No. of animals per sex per dose / concentration:
30 males (10 x 3) gavage; 18 (3 x 6) males i.v. jugular cannula; 10 males i.v. caudal vein
Details on dosing and sampling:
ORAL DOSING GROUP
PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: 5 ml blood from anaesthesized animals via orbital puncture
- Time and frequency of sampling: 5, 10, 20, 30, 45, 60, 90, 120, 240, 480 min after dosing
- From how many animals: 3 animals per time point
- Method type(s) for identification: GC-MS

I.V. (jugular cannula) DOSING GROUP
PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: 0.5 ml blood from non-anaesthesized animals via implanted jugular cannula.
- Time and frequency of sampling: 5, 10, 20, 30, 45, 60, 90, 120, 240, 480 min after dosing
- From how many animals: all animals per time point for blood
- Method type(s) for identification: GC-MS

I.V. (caudal vein) DOSING GROUP
PHARMACOKINETIC STUDY (Absorption, distribution, excretion) AND METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: 0.5 ml blood from orbital puncture followed by urine sampling in metabolic cages
- Time and frequency of sampling: 2, 4, 6, 8, 10, 16 and 24 hr after dosing
- From how many animals: all animals per time point
- Method type(s) for identification: GC-MS

Results and discussion

Main ADME resultsopen allclose all
Type:
absorption
Results:
(oral) bioavailability factor F = 0.018
Type:
distribution
Results:
minimal tissue distribution; volume of distribution 4 ml/ kg bw
Type:
metabolism
Results:
no metabolites identified
Type:
excretion
Results:
92 -96 % via renal clearance

Toxicokinetic / pharmacokinetic studies

Details on absorption:
At pH 7, ethylenediamine, +4PO will be a cation, and thus it is not expected to possess high Iipid solubility. The present data support the notion that ethylenediamine, +4PO does not diffuse through cellular membranes with ease. The calculated oral bioavailability factor (F = 0 .018) indicates that only about 2 % of orally administered ethylenediamine +4PO is absorbed through the cells lining the stomach or intestinal walls .
Details on distribution in tissues:
Ethylenediamine, +4PO conformed to a one-compartment model of distribution and is mainly located within the bloodstream. Ethylenediamine, +4PO is rapidly (though poorly) absorbed and virtually 100 % eliminated from the bioodstream within 24 hr following a single dose.
Details on excretion:
The route of elimination is 92-96 % via renal clearance. Ethylenediamine, +4PO excretion rate appears to be a function of simple glomeruiar filtration with negligible tubular reabsorption. However, it was not possible to recover 100 % of all dosed ethylenediamine, +4PO in the urine. Typicaliy 92-95 % recovery was obtained for IV dosing. This suggests that either ethylenediamine, + 4PO may be eliminated to a small extent via the bile (enterohepatic elimination) or that some ethylenediamine, +4PO may be biotransformed to very polar glucuronide conjugates (acetates or D-glucuronate).

Metabolite characterisation studies

Metabolites identified:
no
Details on metabolites:
No metabolites were identified, the only important peak corresponded to ethylenediamine, +4PO.

Any other information on results incl. tables

Pharmocokinetic parameters of ethylenediamine, +4PO:

 Dose [mg/kg] Cpmax [µg /ml]  tmax [min]  F  K [1/min]  Vd [ml]  Half-life [min]  Cl [ml/hr]  AUC iv (µg min /ml)  AUCpo  (µg min /ml)
 50  12.5  40 - 45  0.018  0.0063  0.96  110  0.36  108600  2004
 100  22.3  40 - 45  0.019  0.0056  0.91  105  0.36  185700  3537
 200  45.9  40 - 45  0.018  0.0064  0.88  108  0.34  408000  7438

The data conform to a 'One Compartment Open Model of Distribution'. Ethylenediamine, +4PO is rapidly (though poorly) absorbed (time to Cpmax 40-45 min) and is virtually 100 % eliminated from the bloodstream within 24 hours following a single dose. The route of excretion is 92-96 % via renal clearance (average clearance 0.35 ml/hr). The elimination half-life averaged 108 min, and these data were consistent for doses up to 200 mg/kg bw. The mean first order elimination rate constant (K) was 0.0064 1/min for dosing with 200 mg/kg bw.

(Vd = volume of distribution; Cl = clearance rate; K = elimination rate constant; F = bioavailability factor; AUC = Area under the curve)

Applicant's summary and conclusion